AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2016

Jan 8, 2016

34632_dirs_2016-01-07_bbb2df5e-a9b3-4d0b-8450-6a1ee992079d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2016-01-05

Reporting Person: Dipp Michelle (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-05	Common Stock	D	15452	—	Disposed	971921	Direct

Footnotes

F1: Represents 971,921 shares of common stock and no RSUs. 15,452 RSUs held by the Reporting Person were forfeited in connection with the Reporting Person entering into an Executive Chair Employment Agreement with the Issuer on January 5, 2016, as previously disclosed on the Issuer's Current Report on Form 8-K filed on January 6, 2016. The forfeited RSUs were not sold.